Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant Chemotherapy and Survival After Pelvic Exenteration for Gynecologic Cancers in the COREPEX Study.

JAMA network open·2026
Same author

Validation of the Transcription Association Chromosomal Instability Index Biomarker on RNA Sequencing in Soft Tissue Sarcomas.

JCO precision oncology·2026
Same author

The prognostic impact of celiac lymph node involvement in advanced ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Terminal T-cell exhaustion predicts tumor control independent of immunotherapy in ovarian cancer.

NPJ precision oncology·2026
Same author

Pelvic exenteration for vulvar cancer: contemporary outcomes from a multinational cohort study.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Inguinofemoral lymphadenectomy in 10 steps.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
Same journal

Neoadjuvant Immunotherapy-Based Treatment Versus Chemotherapy Alone in Resectable Locally Advanced dMMR/MSI-H Gastric Cancer: A Real-World Study with Meta-Analysis.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.1K

Endometrial Stromal Sarcoma: An Update.

Giulio Ricotta1, Silvio Andrea Russo1,2, Anna Fagotti2

  • 1Surgical Oncology, Oncopole Claudius Regaud-Institut Universitaire du Cancer Toulouse Oncopole, 31100 Toulouse, France.

Cancers
|June 13, 2025
PubMed
Summary
This summary is machine-generated.

Endometrial stromal sarcoma (ESS) is a rare uterine cancer with low-grade (LG-ESS) and high-grade (HG-ESS) subtypes. Treatment and prognosis vary significantly, with LG-ESS responding to hormonal therapy and HG-ESS requiring chemotherapy.

Keywords:
endometrial stromal sarcomagynecologic oncologyuterine sarcoma

More Related Videos

Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
05:16

Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors

Published on: February 19, 2022

5.9K
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

11.3K

Related Experiment Videos

Last Updated: Jun 16, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.1K
Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
05:16

Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors

Published on: February 19, 2022

5.9K
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

11.3K

Area of Science:

  • Gynecologic Oncology
  • Pathology
  • Medical Genetics

Background:

  • Endometrial stromal sarcoma (ESS) is a rare uterine malignancy comprising 15-20% of uterine sarcomas.
  • ESS is categorized into low-grade (LG-ESS) and high-grade (HG-ESS) subtypes, distinguished by unique histopathological and molecular characteristics.
  • LG-ESS progresses slowly and is associated with JAZF1-SUZ12 fusions, while HG-ESS is aggressive, marked by high mitotic activity, necrosis, and BCOR internal tandem duplication.

Purpose of the Study:

  • To provide a comprehensive overview of the diagnosis, management, and prognosis of endometrial stromal sarcoma.
  • To differentiate between the clinical and molecular features of LG-ESS and HG-ESS.
  • To highlight current treatment strategies and emerging therapeutic avenues for ESS.

Main Methods:

  • Review of histopathological and molecular features defining LG-ESS and HG-ESS.
  • Analysis of surgical management, including hysterectomy and fertility-sparing options.
  • Evaluation of adjuvant therapies, such as hormonal treatments and chemotherapy, based on ESS subtype.

Main Results:

  • Surgical resection is the primary treatment for early-stage ESS; total hysterectomy with bilateral salpingo-oophorectomy is standard.
  • LG-ESS shows favorable outcomes with hormonal therapy (aromatase inhibitors, progestins), while HG-ESS requires chemotherapy (e.g., doxorubicin-based regimens).
  • Prognosis is stage and subtype-dependent; LG-ESS has >90% five-year survival in early stages, whereas HG-ESS has poorer survival rates.

Conclusions:

  • ESS management requires subtype-specific approaches, with distinct treatments for LG-ESS and HG-ESS.
  • Hormonal therapy is effective for LG-ESS, while chemotherapy is the mainstay for HG-ESS.
  • Molecular profiling holds promise for developing personalized therapies to improve outcomes in rare ESS cases.